

**Erratum to the Waiver Allowing the Participation of Alberto Pappo, M.D.**  
At a Meeting of the Oncologic Drugs Advisory Committee  
October 4, 2023

This erratum contains corrections to the waiver issued allowing the participation of Alberto Pappo, M.D., at the October 4, 2023, Meeting of the Oncologic Drugs Advisory Committee. At this meeting, the Committee will discuss new drug application (NDA) 215500, for eflornithine tablets, submitted by USWM, LLC (doing business as U.S. WorldMeds). The proposed indication (use) for this product is to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma who have completed multiagent, multimodality therapy.

For corrections, deleted text was ~~struck through~~. There is no new text.

**Page 1, paragraph 1, sentence 1:** Should read, “Alberto Pappo, M.D., is a standing voting member ~~and Chairperson~~ of the Oncologic Drugs Advisory Committee (ODAC).”

**Page 4, paragraph 1, sentence 1:** Should read, “Accordingly, I recommend that you grant Dr. Alberto Pappo, ~~the Chairperson and~~ a voting member of the Oncologic Drugs Advisory Committee, a waiver from the conflict of interest prohibitions of 18 U.S.C. § 208(a).”